JNCE Jounce Therapeutics


From Benzinga Pro
Raymond James Maintains Outperform on Jounce Therapeutics, Raises Price Target to $15
5 Nov 21
News, Price Target, Analyst Ratings
Raymond James analyst Steven Seedhouse maintains Jounce Therapeutics (NASDAQ:JNCE) with a Outperform and raises the price target from $10 to $15.
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
4 Nov 21
Biotech, Earnings, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK
Jounce Therapeutics Q3 EPS $(0.59) Misses $(0.44) Estimate
4 Nov 21
Earnings, News
Jounce Therapeutics (NASDAQ:JNCE) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.44) by 34.09 percent. This is a 19.18 percent increase over losses of $(0.73) per share
Earnings Scheduled For November 4, 2021
4 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
31 Oct 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, IPOs, Top Stories
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.